Novomix 30 Flexpen (Insulin Aspart)

Insulin aspart is engineered to dissolve quickly after injection, allowing it to bind insulin receptors on muscle and fat cells more rapidly than regular human insulin. This triggers intracellular signaling that moves glucose transporters to the cell surface, facilitating swift glucose uptake from the bloodstream and reducing post‑prandial blood sugar spikes.

The dose of Novomix 30 Flexpen is individualized by a qualified healthcare professional based on factors such as the patient’s current blood‑glucose readings, carbohydrate intake, body weight, renal function, and overall treatment goals. Patients should follow the prescriber’s instructions and adjust dosing only under medical supervision.

Novomix 30 Flexpen is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy or lactation only if the potential benefits justify the potential risks, and decisions should be made in consultation with a obstetrician‑endocrinologist.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Novomix 30 Flexpen. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Novomix 30 Flexpen contains insulin aspart, which has a faster onset of action than regular human insulin and a similar profile to other rapid‑acting analogues such as insulin lispro or glulisine. Clinical efficacy and safety are comparable, with choice often guided by patient preference, pen device familiarity, and formulary considerations.

Novomix 30 Flexpen should be stored in a refrigerator at 2 °C to 8 °C (36 °F to 46 °F). Keep the pen in its original carton, protect it from light, and avoid freezing. Once in use, the pen may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, as indicated on the label.

The medication is delivered via a prefilled, disposable pen that is inserted subcutaneously into the abdomen, thigh or upper arm. The user selects the prescribed dose using the pen’s dial, then presses the injection button to deliver the insulin. Proper technique, site rotation and disposal of used pens are essential for safety.

The most critical risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognise early signs of low blood sugar, monitor glucose regularly, and seek immediate medical help if they experience difficulty breathing, swelling or rash after injection.

Novomix 30 Flexpen should not be used by individuals with a known hypersensitivity to insulin aspart or any excipients in the formulation. It is also contraindicated in patients experiencing hypoglycaemia at the time of dosing. Clinicians must assess suitability in patients with severe renal or hepatic impairment, and in those with unstable cardiovascular conditions.